Biosimilar Industry Research Report 2023
Highlights
The global Biosimilar market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North American market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
The major global companies of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
The global market for Biosimilar in Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Biosimilar Monoclonal Antibodies, which accounted for % of the global market of Biosimilar in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
The Biosimilar market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Biosimilar type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Biosimilar are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Biosimilar segment by Type
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar market.
Biosimilar Segment by Application
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
The global Biosimilar market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
North American market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
The major global companies of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
The global market for Biosimilar in Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Biosimilar Monoclonal Antibodies, which accounted for % of the global market of Biosimilar in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar.
The Biosimilar market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Biosimilar market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Qilu Pharmaceutical
- Bio-Thera
- Zhejiang Hisun
- Shanghai Henlius
- Innovent Biologics
- Jiangsu Hengrui
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- 3SBIO
- Luye Pharma
Global markets are presented by Biosimilar type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Biosimilar are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Biosimilar segment by Type
- Biosimilar Monoclonal Antibodies
- Biosimilar Insulin
- Others
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biosimilar market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biosimilar market.
Biosimilar Segment by Application
- Cancer
- Immunological Diseases
- Diabetes
- Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biosimilar market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biosimilar industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Biosimilar by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
2.3 Biosimilar by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Cancer
2.3.3 Immunological Diseases
2.3.4 Diabetes
2.3.5 Others
2.4 Assumptions and Limitations
3 BIOSIMILAR BREAKDOWN DATA BY TYPE
3.1 Global Biosimilar Historic Market Size by Type (2018-2023)
3.2 Global Biosimilar Forecasted Market Size by Type (2023-2028)
4 BIOSIMILAR BREAKDOWN DATA BY APPLICATION
4.1 Global Biosimilar Historic Market Size by Application (2018-2023)
4.2 Global Biosimilar Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Biosimilar Market Perspective (2018-2029)
5.2 Global Biosimilar Growth Trends by Region
5.2.1 Global Biosimilar Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Biosimilar Historic Market Size by Region (2018-2023)
5.2.3 Biosimilar Forecasted Market Size by Region (2024-2029)
5.3 Biosimilar Market Dynamics
5.3.1 Biosimilar Industry Trends
5.3.2 Biosimilar Market Drivers
5.3.3 Biosimilar Market Challenges
5.3.4 Biosimilar Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Biosimilar Players by Revenue
6.1.1 Global Top Biosimilar Players by Revenue (2018-2023)
6.1.2 Global Biosimilar Revenue Market Share by Players (2018-2023)
6.2 Global Biosimilar Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Biosimilar Head office and Area Served
6.4 Global Biosimilar Players, Product Type & Application
6.5 Global Biosimilar Players, Date of Enter into This Industry
6.6 Global Biosimilar Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Biosimilar Market Size (2018-2029)
7.2 North America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Biosimilar Market Size by Country (2018-2023)
7.4 North America Biosimilar Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Biosimilar Market Size (2018-2029)
8.2 Europe Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Biosimilar Market Size by Country (2018-2023)
8.4 Europe Biosimilar Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilar Market Size (2018-2029)
9.2 Asia-Pacific Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Biosimilar Market Size by Country (2018-2023)
9.4 Asia-Pacific Biosimilar Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Biosimilar Market Size (2018-2029)
10.2 Latin America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Biosimilar Market Size by Country (2018-2023)
10.4 Latin America Biosimilar Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilar Market Size (2018-2029)
11.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Biosimilar Market Size by Country (2018-2023)
11.4 Middle East & Africa Biosimilar Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Qilu Pharmaceutical
11.1.1 Qilu Pharmaceutical Company Detail
11.1.2 Qilu Pharmaceutical Business Overview
11.1.3 Qilu Pharmaceutical Biosimilar Introduction
11.1.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2017-2022)
11.1.5 Qilu Pharmaceutical Recent Development
11.2 Bio-Thera
11.2.1 Bio-Thera Company Detail
11.2.2 Bio-Thera Business Overview
11.2.3 Bio-Thera Biosimilar Introduction
11.2.4 Bio-Thera Revenue in Biosimilar Business (2017-2022)
11.2.5 Bio-Thera Recent Development
11.3 Zhejiang Hisun
11.3.1 Zhejiang Hisun Company Detail
11.3.2 Zhejiang Hisun Business Overview
11.3.3 Zhejiang Hisun Biosimilar Introduction
11.3.4 Zhejiang Hisun Revenue in Biosimilar Business (2017-2022)
11.3.5 Zhejiang Hisun Recent Development
11.4 Shanghai Henlius
11.4.1 Shanghai Henlius Company Detail
11.4.2 Shanghai Henlius Business Overview
11.4.3 Shanghai Henlius Biosimilar Introduction
11.4.4 Shanghai Henlius Revenue in Biosimilar Business (2017-2022)
11.4.5 Shanghai Henlius Recent Development
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Detail
11.5.2 Innovent Biologics Business Overview
11.5.3 Innovent Biologics Biosimilar Introduction
11.5.4 Innovent Biologics Revenue in Biosimilar Business (2017-2022)
11.5.5 Innovent Biologics Recent Development
11.6 Jiangsu Hengrui
11.6.1 Jiangsu Hengrui Company Detail
11.6.2 Jiangsu Hengrui Business Overview
11.6.3 Jiangsu Hengrui Biosimilar Introduction
11.6.4 Jiangsu Hengrui Revenue in Biosimilar Business (2017-2022)
11.6.5 Jiangsu Hengrui Recent Development
11.7 Gan&Lee
11.7.1 Gan&Lee Company Detail
11.7.2 Gan&Lee Business Overview
11.7.3 Gan&Lee Biosimilar Introduction
11.7.4 Gan&Lee Revenue in Biosimilar Business (2017-2022)
11.7.5 Gan&Lee Recent Development
11.8 Tonghua Dongbao
11.8.1 Tonghua Dongbao Company Detail
11.8.2 Tonghua Dongbao Business Overview
11.8.3 Tonghua Dongbao Biosimilar Introduction
11.8.4 Tonghua Dongbao Revenue in Biosimilar Business (2017-2022)
11.8.5 Tonghua Dongbao Recent Development
11.9 United Laboratory
11.9.1 United Laboratory Company Detail
11.9.2 United Laboratory Business Overview
11.9.3 United Laboratory Biosimilar Introduction
11.9.4 United Laboratory Revenue in Biosimilar Business (2017-2022)
11.9.5 United Laboratory Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Detail
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Biosimilar Introduction
11.10.4 3SBIO Revenue in Biosimilar Business (2017-2022)
11.10.5 3SBIO Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Detail
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Biosimilar Introduction
11.11.4 Luye Pharma Revenue in Biosimilar Business (2017-2022)
11.11.5 Luye Pharma Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Biosimilar by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
2.3 Biosimilar by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Cancer
2.3.3 Immunological Diseases
2.3.4 Diabetes
2.3.5 Others
2.4 Assumptions and Limitations
3 BIOSIMILAR BREAKDOWN DATA BY TYPE
3.1 Global Biosimilar Historic Market Size by Type (2018-2023)
3.2 Global Biosimilar Forecasted Market Size by Type (2023-2028)
4 BIOSIMILAR BREAKDOWN DATA BY APPLICATION
4.1 Global Biosimilar Historic Market Size by Application (2018-2023)
4.2 Global Biosimilar Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Biosimilar Market Perspective (2018-2029)
5.2 Global Biosimilar Growth Trends by Region
5.2.1 Global Biosimilar Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Biosimilar Historic Market Size by Region (2018-2023)
5.2.3 Biosimilar Forecasted Market Size by Region (2024-2029)
5.3 Biosimilar Market Dynamics
5.3.1 Biosimilar Industry Trends
5.3.2 Biosimilar Market Drivers
5.3.3 Biosimilar Market Challenges
5.3.4 Biosimilar Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Biosimilar Players by Revenue
6.1.1 Global Top Biosimilar Players by Revenue (2018-2023)
6.1.2 Global Biosimilar Revenue Market Share by Players (2018-2023)
6.2 Global Biosimilar Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Biosimilar Head office and Area Served
6.4 Global Biosimilar Players, Product Type & Application
6.5 Global Biosimilar Players, Date of Enter into This Industry
6.6 Global Biosimilar Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Biosimilar Market Size (2018-2029)
7.2 North America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Biosimilar Market Size by Country (2018-2023)
7.4 North America Biosimilar Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Biosimilar Market Size (2018-2029)
8.2 Europe Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Biosimilar Market Size by Country (2018-2023)
8.4 Europe Biosimilar Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilar Market Size (2018-2029)
9.2 Asia-Pacific Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Biosimilar Market Size by Country (2018-2023)
9.4 Asia-Pacific Biosimilar Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Biosimilar Market Size (2018-2029)
10.2 Latin America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Biosimilar Market Size by Country (2018-2023)
10.4 Latin America Biosimilar Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilar Market Size (2018-2029)
11.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Biosimilar Market Size by Country (2018-2023)
11.4 Middle East & Africa Biosimilar Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Qilu Pharmaceutical
11.1.1 Qilu Pharmaceutical Company Detail
11.1.2 Qilu Pharmaceutical Business Overview
11.1.3 Qilu Pharmaceutical Biosimilar Introduction
11.1.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2017-2022)
11.1.5 Qilu Pharmaceutical Recent Development
11.2 Bio-Thera
11.2.1 Bio-Thera Company Detail
11.2.2 Bio-Thera Business Overview
11.2.3 Bio-Thera Biosimilar Introduction
11.2.4 Bio-Thera Revenue in Biosimilar Business (2017-2022)
11.2.5 Bio-Thera Recent Development
11.3 Zhejiang Hisun
11.3.1 Zhejiang Hisun Company Detail
11.3.2 Zhejiang Hisun Business Overview
11.3.3 Zhejiang Hisun Biosimilar Introduction
11.3.4 Zhejiang Hisun Revenue in Biosimilar Business (2017-2022)
11.3.5 Zhejiang Hisun Recent Development
11.4 Shanghai Henlius
11.4.1 Shanghai Henlius Company Detail
11.4.2 Shanghai Henlius Business Overview
11.4.3 Shanghai Henlius Biosimilar Introduction
11.4.4 Shanghai Henlius Revenue in Biosimilar Business (2017-2022)
11.4.5 Shanghai Henlius Recent Development
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Detail
11.5.2 Innovent Biologics Business Overview
11.5.3 Innovent Biologics Biosimilar Introduction
11.5.4 Innovent Biologics Revenue in Biosimilar Business (2017-2022)
11.5.5 Innovent Biologics Recent Development
11.6 Jiangsu Hengrui
11.6.1 Jiangsu Hengrui Company Detail
11.6.2 Jiangsu Hengrui Business Overview
11.6.3 Jiangsu Hengrui Biosimilar Introduction
11.6.4 Jiangsu Hengrui Revenue in Biosimilar Business (2017-2022)
11.6.5 Jiangsu Hengrui Recent Development
11.7 Gan&Lee
11.7.1 Gan&Lee Company Detail
11.7.2 Gan&Lee Business Overview
11.7.3 Gan&Lee Biosimilar Introduction
11.7.4 Gan&Lee Revenue in Biosimilar Business (2017-2022)
11.7.5 Gan&Lee Recent Development
11.8 Tonghua Dongbao
11.8.1 Tonghua Dongbao Company Detail
11.8.2 Tonghua Dongbao Business Overview
11.8.3 Tonghua Dongbao Biosimilar Introduction
11.8.4 Tonghua Dongbao Revenue in Biosimilar Business (2017-2022)
11.8.5 Tonghua Dongbao Recent Development
11.9 United Laboratory
11.9.1 United Laboratory Company Detail
11.9.2 United Laboratory Business Overview
11.9.3 United Laboratory Biosimilar Introduction
11.9.4 United Laboratory Revenue in Biosimilar Business (2017-2022)
11.9.5 United Laboratory Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Detail
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Biosimilar Introduction
11.10.4 3SBIO Revenue in Biosimilar Business (2017-2022)
11.10.5 3SBIO Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Detail
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Biosimilar Introduction
11.11.4 Luye Pharma Revenue in Biosimilar Business (2017-2022)
11.11.5 Luye Pharma Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biosimilar Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Biosimilar Revenue Market Share by Type (2018-2023)
Table 7. Global Biosimilar Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Biosimilar Revenue Market Share by Type (2024-2029)
Table 9. Global Biosimilar Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Biosimilar Revenue Market Share by Application (2018-2023)
Table 11. Global Biosimilar Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Biosimilar Revenue Market Share by Application (2024-2029)
Table 13. Global Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Biosimilar Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Biosimilar Market Share by Region (2018-2023)
Table 16. Global Biosimilar Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Biosimilar Market Share by Region (2024-2029)
Table 18. Biosimilar Market Trends
Table 19. Biosimilar Market Drivers
Table 20. Biosimilar Market Challenges
Table 21. Biosimilar Market Restraints
Table 22. Global Top Biosimilar Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Biosimilar Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Biosimilar Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Biosimilar, Headquarters and Area Served
Table 26. Global Biosimilar Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Biosimilar by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 45. Qilu Pharmaceutical Company Detail
Table 46. Qilu Pharmaceutical Business Overview
Table 47. Qilu Pharmaceutical Biosimilar Product
Table 48. Qilu Pharmaceutical Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 49. Qilu Pharmaceutical Recent Development
Table 50. Bio-Thera Company Detail
Table 51. Bio-Thera Business Overview
Table 52. Bio-Thera Biosimilar Product
Table 53. Bio-Thera Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 54. Bio-Thera Recent Development
Table 55. Zhejiang Hisun Company Detail
Table 56. Zhejiang Hisun Business Overview
Table 57. Zhejiang Hisun Biosimilar Product
Table 58. Zhejiang Hisun Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 59. Zhejiang Hisun Recent Development
Table 60. Shanghai Henlius Company Detail
Table 61. Shanghai Henlius Business Overview
Table 62. Shanghai Henlius Biosimilar Product
Table 63. Shanghai Henlius Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 64. Shanghai Henlius Recent Development
Table 65. Innovent Biologics Company Detail
Table 66. Innovent Biologics Business Overview
Table 67. Innovent Biologics Biosimilar Product
Table 68. Innovent Biologics Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 69. Innovent Biologics Recent Development
Table 70. Jiangsu Hengrui Company Detail
Table 71. Jiangsu Hengrui Business Overview
Table 72. Jiangsu Hengrui Biosimilar Product
Table 73. Jiangsu Hengrui Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 74. Jiangsu Hengrui Recent Development
Table 75. Gan&Lee Company Detail
Table 76. Gan&Lee Business Overview
Table 77. Gan&Lee Biosimilar Product
Table 78. Gan&Lee Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 79. Gan&Lee Recent Development
Table 80. Tonghua Dongbao Company Detail
Table 81. Tonghua Dongbao Business Overview
Table 82. Tonghua Dongbao Biosimilar Product
Table 83. Tonghua Dongbao Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 84. Tonghua Dongbao Recent Development
Table 85. United Laboratory Company Detail
Table 86. United Laboratory Business Overview
Table 87. United Laboratory Biosimilar Product
Table 88. United Laboratory Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 89. United Laboratory Recent Development
Table 90. 3SBIO Company Detail
Table 91. 3SBIO Business Overview
Table 92. 3SBIO Biosimilar Product
Table 93. 3SBIO Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 94. 3SBIO Recent Development
Table 95. Luye Pharma Company Detail
Table 96. Luye Pharma Business Overview
Table 97. Luye Pharma BiosimilarProduct
Table 98. Luye Pharma Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 99. Luye Pharma Recent Development
Table 100. Qilu Pharmaceutical Company Information
Table 101. Qilu Pharmaceutical Business Overview
Table 102. Qilu Pharmaceutical Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 103. Qilu Pharmaceutical Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 104. Qilu Pharmaceutical Recent Development
Table 105. Bio-Thera Company Information
Table 106. Bio-Thera Business Overview
Table 107. Bio-Thera Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 108. Bio-Thera Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 109. Bio-Thera Recent Development
Table 110. Zhejiang Hisun Company Information
Table 111. Zhejiang Hisun Business Overview
Table 112. Zhejiang Hisun Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 113. Zhejiang Hisun Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 114. Zhejiang Hisun Recent Development
Table 115. Shanghai Henlius Company Information
Table 116. Shanghai Henlius Business Overview
Table 117. Shanghai Henlius Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 118. Shanghai Henlius Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 119. Shanghai Henlius Recent Development
Table 120. Innovent Biologics Company Information
Table 121. Innovent Biologics Business Overview
Table 122. Innovent Biologics Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 123. Innovent Biologics Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 124. Innovent Biologics Recent Development
Table 125. Jiangsu Hengrui Company Information
Table 126. Jiangsu Hengrui Business Overview
Table 127. Jiangsu Hengrui Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 128. Jiangsu Hengrui Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 129. Jiangsu Hengrui Recent Development
Table 130. Gan&Lee Company Information
Table 131. Gan&Lee Business Overview
Table 132. Gan&Lee Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 133. Gan&Lee Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 134. Gan&Lee Recent Development
Table 135. Tonghua Dongbao Company Information
Table 136. Tonghua Dongbao Business Overview
Table 137. Tonghua Dongbao Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 138. Tonghua Dongbao Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 139. Tonghua Dongbao Recent Development
Table 140. United Laboratory Company Information
Table 141. United Laboratory Business Overview
Table 142. United Laboratory Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 143. United Laboratory Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 144. United Laboratory Recent Development
Table 145. 3SBIO Company Information
Table 146. 3SBIO Business Overview
Table 147. 3SBIO Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 148. 3SBIO Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 149. 3SBIO Recent Development
Table 150. Luye Pharma Company Information
Table 151. Luye Pharma Business Overview
Table 152. Luye Pharma BiosimilarRevenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 153. Luye Pharma Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biosimilar Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Biosimilar Revenue Market Share by Type (2018-2023)
Table 7. Global Biosimilar Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Biosimilar Revenue Market Share by Type (2024-2029)
Table 9. Global Biosimilar Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Biosimilar Revenue Market Share by Application (2018-2023)
Table 11. Global Biosimilar Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Biosimilar Revenue Market Share by Application (2024-2029)
Table 13. Global Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Biosimilar Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Biosimilar Market Share by Region (2018-2023)
Table 16. Global Biosimilar Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Biosimilar Market Share by Region (2024-2029)
Table 18. Biosimilar Market Trends
Table 19. Biosimilar Market Drivers
Table 20. Biosimilar Market Challenges
Table 21. Biosimilar Market Restraints
Table 22. Global Top Biosimilar Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Biosimilar Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Biosimilar Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Biosimilar, Headquarters and Area Served
Table 26. Global Biosimilar Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Biosimilar by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Biosimilar Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Biosimilar Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Biosimilar Market Size by Country (2024-2029) & (US$ Million)
Table 45. Qilu Pharmaceutical Company Detail
Table 46. Qilu Pharmaceutical Business Overview
Table 47. Qilu Pharmaceutical Biosimilar Product
Table 48. Qilu Pharmaceutical Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 49. Qilu Pharmaceutical Recent Development
Table 50. Bio-Thera Company Detail
Table 51. Bio-Thera Business Overview
Table 52. Bio-Thera Biosimilar Product
Table 53. Bio-Thera Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 54. Bio-Thera Recent Development
Table 55. Zhejiang Hisun Company Detail
Table 56. Zhejiang Hisun Business Overview
Table 57. Zhejiang Hisun Biosimilar Product
Table 58. Zhejiang Hisun Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 59. Zhejiang Hisun Recent Development
Table 60. Shanghai Henlius Company Detail
Table 61. Shanghai Henlius Business Overview
Table 62. Shanghai Henlius Biosimilar Product
Table 63. Shanghai Henlius Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 64. Shanghai Henlius Recent Development
Table 65. Innovent Biologics Company Detail
Table 66. Innovent Biologics Business Overview
Table 67. Innovent Biologics Biosimilar Product
Table 68. Innovent Biologics Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 69. Innovent Biologics Recent Development
Table 70. Jiangsu Hengrui Company Detail
Table 71. Jiangsu Hengrui Business Overview
Table 72. Jiangsu Hengrui Biosimilar Product
Table 73. Jiangsu Hengrui Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 74. Jiangsu Hengrui Recent Development
Table 75. Gan&Lee Company Detail
Table 76. Gan&Lee Business Overview
Table 77. Gan&Lee Biosimilar Product
Table 78. Gan&Lee Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 79. Gan&Lee Recent Development
Table 80. Tonghua Dongbao Company Detail
Table 81. Tonghua Dongbao Business Overview
Table 82. Tonghua Dongbao Biosimilar Product
Table 83. Tonghua Dongbao Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 84. Tonghua Dongbao Recent Development
Table 85. United Laboratory Company Detail
Table 86. United Laboratory Business Overview
Table 87. United Laboratory Biosimilar Product
Table 88. United Laboratory Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 89. United Laboratory Recent Development
Table 90. 3SBIO Company Detail
Table 91. 3SBIO Business Overview
Table 92. 3SBIO Biosimilar Product
Table 93. 3SBIO Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 94. 3SBIO Recent Development
Table 95. Luye Pharma Company Detail
Table 96. Luye Pharma Business Overview
Table 97. Luye Pharma BiosimilarProduct
Table 98. Luye Pharma Revenue in Biosimilar Business (2017-2022) & (US$ Million)
Table 99. Luye Pharma Recent Development
Table 100. Qilu Pharmaceutical Company Information
Table 101. Qilu Pharmaceutical Business Overview
Table 102. Qilu Pharmaceutical Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 103. Qilu Pharmaceutical Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 104. Qilu Pharmaceutical Recent Development
Table 105. Bio-Thera Company Information
Table 106. Bio-Thera Business Overview
Table 107. Bio-Thera Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 108. Bio-Thera Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 109. Bio-Thera Recent Development
Table 110. Zhejiang Hisun Company Information
Table 111. Zhejiang Hisun Business Overview
Table 112. Zhejiang Hisun Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 113. Zhejiang Hisun Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 114. Zhejiang Hisun Recent Development
Table 115. Shanghai Henlius Company Information
Table 116. Shanghai Henlius Business Overview
Table 117. Shanghai Henlius Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 118. Shanghai Henlius Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 119. Shanghai Henlius Recent Development
Table 120. Innovent Biologics Company Information
Table 121. Innovent Biologics Business Overview
Table 122. Innovent Biologics Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 123. Innovent Biologics Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 124. Innovent Biologics Recent Development
Table 125. Jiangsu Hengrui Company Information
Table 126. Jiangsu Hengrui Business Overview
Table 127. Jiangsu Hengrui Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 128. Jiangsu Hengrui Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 129. Jiangsu Hengrui Recent Development
Table 130. Gan&Lee Company Information
Table 131. Gan&Lee Business Overview
Table 132. Gan&Lee Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 133. Gan&Lee Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 134. Gan&Lee Recent Development
Table 135. Tonghua Dongbao Company Information
Table 136. Tonghua Dongbao Business Overview
Table 137. Tonghua Dongbao Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 138. Tonghua Dongbao Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 139. Tonghua Dongbao Recent Development
Table 140. United Laboratory Company Information
Table 141. United Laboratory Business Overview
Table 142. United Laboratory Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 143. United Laboratory Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 144. United Laboratory Recent Development
Table 145. 3SBIO Company Information
Table 146. 3SBIO Business Overview
Table 147. 3SBIO Biosimilar Revenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 148. 3SBIO Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
Table 149. 3SBIO Recent Development
Table 150. Luye Pharma Company Information
Table 151. Luye Pharma Business Overview
Table 152. Luye Pharma BiosimilarRevenue in Biosimilar Business (2018-2023) & (US$ Million)
Table 153. Luye Pharma Revenue in Biosimilar Business (2018-2023) & (US$ Million) Portfolio
